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Abstract
Background: Angiotensin (Ang) II and Ang-(1-7) are two of the bioactive peptides of the rennin-angiotensin system. Ang II
is involved in the development of cardiovascular disease, such as hypertension and atherosclerosis, while Ang-(1-7) shows
cardiovascular protection in contrast to Ang II.
Methodology/Principal Findings: In this study, we investigated effects of Ang II and Ang-(1-7) on vascular smooth muscle
cell (SMC) proliferation and migration, which are critical in the formation of atherosclerotic lesions. Treatment with Ang II
resulted in an increase of SMC proliferation, whereas Ang-(1-7) alone had no effects. However, preincubation with Ang-(1-7)
inhibited Ang II-induced SMC proliferation. Ang II promoted SMC migration, and this effect was abolished by pretreatment
with Ang-(1-7). The stimulatory effects of Ang II on SMC proliferation and migration were blocked by the Ang II receptor
antagonist lorsartan, while the inhibitory effects of Ang-(1-7) were abolished by the Ang-(1-7) receptor antagonist A-799.
Ang II treatment caused activation of ERK1/2 mediated signaling, and this was inhibited by preincubation of SMCs with
Ang-(1-7).
Conclusion: These results suggest that Ang-(1-7) inhibits Ang II-induced SMC proliferation and migration, at least in part,
through negative modulation of Ang II induced ERK1/2 activity.
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Introduction
Vascular smooth muscle cell migration and proliferation are
important processes in the development of restenosis after
angioplasty and in the formation of atherosclerotic plaques
[1,2]. After angioplasty, SMCs migrate from media into intima,
where they contribute to neointima formation and restenosis.
This process is also an important feature in the development of de
nova atherosclerotic lesions, in which fibrous cap is characterized
by the accumulation of SMCs and SMC-derived extracellular
matrix.
Angiotensin II, one of the major active components in the
rennin-angiotensin system, plays an essential role in the patho-
genesis of atherosclerosis [3]. Most of the pathophysiologic actions
of Ang II are mediated by signal transduction through the AT1
receptor. The AT1 receptor, which contains 7 transmembrane
helixes, is a member of superfamily of G protein-coupled
receptors. This receptor mediates the effects of Ang II on
vasoconstriction, proliferation, inflammation, coagulation and
extracellular matrix remodeling.[4] During the development of
atherosclerosis, Ang II, acting through AT1 receptor, induces
vascular SMC growth and migration [1,4].
An major Ang II-induced signaling pathway is activation of
mitogen-activated protein kinases, including extracellular signal-
regulated kinase (ERK1/2) [5], p38 mitogen-activated protein
kinase (p38 MAPK) [6], and c-Jun N-terminal kinase (c-JNK) [7].
ERK1/2 has been reported to be a critical regulatory factor for
Ang II-mediated growth and migration of vascular SMCs [5,8–
11], Inhibition of ERK1/2 decreases Ang II-induced vascular
SMC proliferation and migration [5,11].
Angiotensin-(1-7), another bioactive peptide of the rennin-angio-
tensin system, appears to exert cardiovascular protection in contrast to
Ang II. Ang-(1-7), which can be converted from Ang II by ACE2, has
vasodilator and anti-proliferative properties [12]. In addition, it has
been shown that Ang-(1-7) attenuates ventricular hypertrophy and
fibrosis in response to the hypertensive challenge by Ang II [13]. The
effects of Ang-(1-7) are mediated via the MAS receptor, another G-
protein-coupled, seven transmembrane protein [14]. The peptide has
been shown to oppose many actions of Ang II [15], and to
counterregulate Ang II-induced ERK1/2 activity [16–18].
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12323There are studies showing the effect of Ang-(1-7) on vascular
SMC proliferation [16,19]. Nevertheless, the effect of Ang-(1-7) on
vascular SMC migration has not been well investigated. There is
evidence showing that intravenouse infusions of Ang-(1-7)
attenuates neointimal formation after vascular injury and stent
implantation in rats [20,21], which could be in part due to effects
of Ang-(1-7) on SMC migration into the neointima. In this study,
we investigated possible effects of Ang-(1-7) on vascular SMC
proliferation and migration. We found that Ang-(1-7) inhibited
Ang II-induced vascular SMC proliferation and migration, and
this inhibitory effect was via the MAS receptor. Furthermore, we
found that Ang-(1-7) treatment suppressed Ang II-induced
activation of ERK1/2 mediated signaling, a possible mechanism
for its inhibitory effect on SMC proliferation and migration.
Results
Ang-(1-7) inhibits Ang II-induced SMC proliferation
RT-PCR and subsequent sequence analysis showed that the
SMCs expressed both the Ang II AT1 receptor and the Ang-(1-7)
MAS receptor. To study effects of Ang II and Ang-(1-7) on SMC
proliferation, same numbers of cells were seeded in individual wells
of 6-well plates, cultured in the presence or absence of Ang II or
Ang-(1-7) or both (Ang-(1-7) was added 10 min before the addition
of Ang II) at a final concentration of 10
27 M for four days, and
then the total numbers of cells per well were determined using a
cell counter. As shown in Figure 1, there was a significantly greater
increase in cell number when treated with Ang II, as compared
with the untreated control. In contrast, treatment with Ang-(1-7)
alone did not alter the rate of cell proliferation. However, when
the cells were preincubated with Ang-(1-7), Ang II-induced SMC
proliferation was significantly inhibited (Figure 1).
MAS receptor antagonist abrogates the effects of
Ang-(1-7) on SMC proliferation
As Ang II mediates most of its effects via the AT1 receptor and
Ang-(1-7) mediates its effects via the MAS receptor, we then used
the AT1 receptor antagonist losartan and the MAS receptor
antagonist A-779 to investigate whether Ang II and Ang-(1-7)
exerted their effects on SMC proliferation via these two receptors
respectively. As shown in Figure 2, the AT1 receptor antagonist
losartan blocked Ang II-induced SMC proliferation, whilst the
MAS receptor antagonist A-779 abrogated the anti-proliferative
effect of Ang-(1-7) on Ang II-induced SMC proliferation.
Ang-(1-7) modulates Ang II-stimulated SMC migration
To study effects of Ang II and Ang-(1-7) on SMC migration,
SMCs were subjected to migration assays, in the presences or
absence of Ang II or Ang-(1-7) or both (Ang-(1-7) was added
10 min before the addition of Ang II). The experiments showed
that Ang II increased SMC migration, whereas Ang-(1-7) alone
had no effect (Figure 3). However, cells treated with both Ang II
and Ang-(1-7) had significant lower rate of migration compared
with cells treated with Ang II alone (Figure 3), suggesting that
Ang-(1-7) inhibited the stimulating effect of Ang II on SMC m
igration.
Figure 1. Ang-(1-7) inhibits Ang II-induced SMC proliferation.
Data shown are mean 6 SEM of cell numbers at day 4 from 4
experiments, each with triplicate wells per condition.
doi:10.1371/journal.pone.0012323.g001
Figure 2. Antagonists abrogate the effects of Ang II and Ang-
(1-7) on SMC proliferation. Data shown are mean 6 SEM of cell
numbers at day 4 from 4 experiments, each with triplicate wells per
condition.
doi:10.1371/journal.pone.0012323.g002
Figure 3. Ang-(1-7) inhibits the stimulating effect of Ang II on
SMC migration. Data shown are mean 6 SEM of migration distance
from 4 experiments, each with triplicate wells per condition.
doi:10.1371/journal.pone.0012323.g003
Angiotensin and SMC Migration
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on SMC migration
To investigate whether the stimulating effect of SMC migration
was mediated via the AT1 receptor and whether the counteracting
effect of Ang-(1-7) was mediated by the MAS receptor, we
performed the migration assays in the presence or absence of the
AT1 receptor antagonist losartan or the MAS receptor antagonist
A-779. As shown in Figure 4, Ang II-induced SMC migration was
inhibited by AT1R antagonist losartan, while the inhibitory effect
of Ang-(1-7) on Ang II-induced SMC migration was blocked by
A-779.
Ang-(1-7) inhibits AngII-induced ERK1/2 phosphorylation
Since the ERK1/2 signaling pathway plays a major role in Ang
II-induced SMC proliferation and migration[5,11], we investigat-
ed whether Ang-(1-7) interfered with Ang II-induced ERK1/2
activation. We found that Ang II treatment stimulated phosphor-
ylation of ERK1/2 and that this effect was significantly inhibited
in the presence of Ang-(1-7) (Figure 5).
Discussion
Our study show that Ang-(1-7) and Ang II exert different effects
on vascular SMC proliferation and migration. Our study confirms
the reported stimulating effects of Ang II on SMC proliferation
and migration, supporting the notion that increased Ang II
generation can promotes atherogenesis and neointimal formation
leading to restenosis after angioplasty [22]. Similar to previous
studies which showed that Ang-(1-7) inhibits proliferation in a
number of cell types [19,23-25], we observed that Ang-(1-7)
negatively modulates Ang II-induced vascular SMC proliferation.
Besides, the most important finding of our study is that Ang-(1-7)
inhibits Ang II-induced SMC migration. This novel finding
provides a further rationale for the use of Ang-(1-7) as a
therapeutic agent for preventing neointimal formation and
restenosis after angioplasty [26,27]. We found that the inhibitory
effect of Ang-(1-7) on Ang II-stimulated SMC proliferation and
migration can be blocked by the MAS receptor antagonist A-779,
indicating that Ang-(1-7) exerts this effect via activating the MAS
receptor. Furthermore, we show that Ang-(1-7) inhibits Ang II-
induced ERK1/2 phosphorylation, which provides a plausible
explanation for the molecular mechanism underlying the inhib-
itory effect of Ang-(1-7) on Ang II stimulated SMC proliferation
and migration, since the ERK1/2 dependent signaling pathway
plays a critical role in mediating the stimulating effect of Ang II on
SMC proliferation and migration.
In our study, we observed that Ang-(1-7) inhibits Ang II-induced
vascular SMC proliferation. Interestingly, whilst Ang II has been
shown to induce proliferation of many cell types including vascular
SMCs,[22] divergent effects have been reported for Ang-(1-7) in
different cell types. It has been shown that Ang-(1-7) causes
inhibition of proliferation of rat vascular SMCs, myocytes and
human lung cancer cells,[19,23,24] and that Ang-(1-7) treatment
attenuates neointimal formation after stent implantation in rats.[20]
On the other hand, Ang-(1-7) simulates proliferation of endothelia
progenitor cells and hematopoietic progenitor cells [28,29].
Moreover, similar to our finding in mouse SMCs, Ang-(1-7) alone
has no effect on mesangial cell growth, whereas Ang-(1-7) inhibits
Ang II-induced increase in mesangial cell proliferation [25]. The
reasons for these divergent effects of Ang-(1-7) are currently
unknown and might be due to differences in the repertoires of
receptors, signaling molecules and cell cycling regulators, etc, in the
different types of cells. There is a reported study showing direct
inhibition of rat vascular SMC proliferation by Ang-(1-7) [19],
which differ from our finding in mouse SMCs, possibly because of
the different animal specials and experiment conditions.
It has been well established that Ang II is a potent stimulus for
vascular SMC migration [5,6,8,10,30]. In contrast, it was unclear
whether Ang-(1-7) also had a effect on SMC migration, although
there are several studies from which there is indirect evidence to
suggest that this might be the case. Some of these studies showed that
Ang-(1-7) treatment attenuated neointimal formation after vascular
injury and stent implantation in the rat [20,27]. Similarly, another
study showed that Ang-(1-7) treatment resulted in a reduction of
neointimal formation and collagen synthesis after angioplasty in
rabbits [26]. As SMC migration is a critical step in the formation of
neointima, it is possible that the reduction in neointimal formation as
a result of Ang-(1-7) in these studies might be in part due to an
inhibitory effect of Ang-(1-7) on SMC migration. The finding of our
studythatAng-(1-7)inhibitsAngII-inducedSMCmigrationprovides
direct evidence that supports this notion.
Our study shows that Ang II-induced ERK1/2 activation is
negatively modulated by Ang-(1-7). Previous studies have shown
that activation of ERK1/2 plays an important role in SMC
migration. ERK1 and ERK2 are rapidly activated in rat carotid
arteries after balloon injury [31]. Downregulation of ERK1/2 by
antisense oligonucleotides or gene transfer of a dominant-negative
mutant of ERK1/2 prevents neointimal formation in balloon
angioplasty [32]. In addition, it has been shown that the effect of
Ang II on vascular SMC migration are mediated via an AT1
receptor dependent signaling pathway involving activation of
ERK1/2 [9], and that blocking ERK1/2 activation using the
MAPK kinase inhibitor PD98059 or antisense oligodeoxynucleo-
tides can significantly attenuate Ang II-stimulated SMC migration
[5]. In the present study, we found that Ang-(1-7) reduced Ang II-
stimulated ERK1/2 activity. It is likely that Ang-(1-7) can activate
a signaling pathway that leads to blockage of ERK1/2 activation
and therefore can inhibit Ang II- induced ERK activation and
Ang II-stimulated SMC migration.
Figure 4. Blockade of the effects of Ang II and Ang-(1-7) on
SMC migration by antagonists. Data shown are mean 6 SEM of
migration distance from 4 experiments, each with triplicate wells per
condition.
doi:10.1371/journal.pone.0012323.g004
Angiotensin and SMC Migration
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7) regulates SMC migration. Firstly, inhibition of the ERK1/2-
dependant signally cascade by Ang-(1-7) is likely to play a role in
reduced cell migration. Substrates of ERK1/2 include FAK (focal
adhesion kinase) and paxillin [33,34]. ERK1/2-dependant FAK and
paxillin phosphorylation is important in the regulation of focal
contacts during cell migration [35]. Ang II-induced activation of c-
Src, another vital component in the regulation of focal contacts
formation, has been shown to be abrogated by Ang-(1-7) in human
endothelial cells, and c-Src is upstream of the ERK signaling cascade
[18]. Ang-(1-7) antagonizes Ang II-mediated upregulation of matrix
metalloproteinase (MMP)-9 [36], an extracellular matrix protein-
degrading enzyme known to play an important role in cell migration
[37]. MMP-9 expression has been shown to be mediated by ERK1/
2, and inhibition of ERK1/2 downregulates MMP-9 expression in
vascular SMCs and in arterialized vein grafts [38,39]. As our study
showed that Ang-(1-7) abrogated Ang II-mediated ERK1/2
activation, it is likely that Ang-(1-7) can counteract Ang II-induced
SMC migration through inhibiting FAK and paxillin phosphoryla-
tion and MMP-9 expression via the ERK1/2 pathway. Secondly,
Ang-(1-7) is a bioactive peptide that stimulates nitric oxide release
[40,41], and nitric oxide is known to inhibit Ang II-induced SMC
migration [40,42]. Thirdly, Ang-(1-7) can downregulate AT1
receptor, resulting in reduced Ang II binding in vascular SMCs [43].
The first evidence for an interaction between Ang-(1-7) and Ang
II is the inhibition of the contractile effect of Ang II in the rabbit
aorta by the Ang-(1-7) analogue Sar-Ang-(1-7) [44]. Further studies
show that Ang-(1-7) antagonizes Ang II-induced contraction of
human vessels, including internal mammary arteries and forearm
resistant vessels [28,45,46]. Ang-(1-7) blockade of Ang II-induced
contraction results from release of vasorelaxing factors including
NO and prostaglandins [40], or other biologically active peptides
such as bradykinin [47]. In addition, it has been shown that Ang-(1-
7) prevents Ang II-induced cardiac remodeling, attenuating
myocyte hypertrophy and myocardial interstitial fibrosis induced
by Ang II [48]. The finding of our study that Ang-(1-7) inhibits the
effect of Ang II on SMC proliferation and migration suggests that
the interaction between Ang-(1-7) and Ang II could also occur in
vascular remodeling via affecting SMC proliferation and migration.
Thefindingsfrom the previousandpresent studies of differenteffects
of Ang II and Ang-(1-7), which represent two major members of the
rennin-angiotensin system, are directly relevant to understanding the
Figure 5. Ang-(1-7) inhibits Ang II-induced ERK1/2 phosphorylation. (A) Representative Western blotting results, showing bands for
phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2. (B) Quantification of band intensity of Western blots. Data shown are mean 6 SEM of 3
experiments.
doi:10.1371/journal.pone.0012323.g005
Angiotensin and SMC Migration
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angioplasty. Moreover, the findings that Ang-(1-7) counteracts the
atherogenic effect of Ang II have led to the development of therapeutic
approaches utilizing the anti-atherogenic properties of Ang-(1-7), e.g.
Ang-(1-7) coated stents [20]. The novel finding of the present study that
Ang-(1-7) inhibits Ang II-induced SMC migration further supports the
rationales for such therapeutic approaches.
Materials and Methods
Materials
Ang II, Ang-(1-7), losartan, Dulbecco’s modified Eagle’s medium
(DMEM), penicillin and streptomycin were obtained from Sigma
Aldrich. A-779 was purchased from PhoenixPharmaceuticals. Fetal
bovine serum (FBS) was obtained from Invitrogen. Antibodies to
phospho-ERK1/2 and to total ERK1/2 were from Cell signaling.
Cell culture
SMCs were isolated by autogrowth of explant culture from the
thoracic aortas of mice as described before [49], which was
approved by King’s College Ethical Review Process Committee
and under the UK Home Office Animal Scientific Procedures
Division permit number 70/6458. Briefly, mouse thoracic aortas
were removed and washed with DMEM. Intima and inner two
thirds of media were carefully dissected from the vessels, cut into
pieces (<1m m
3). Tissue pieces were then explanted onto a 0.02%
gelatin-coated flask. To get a firm attachment of tissue pieces, the
flask was incubated upside-down for 1 h and then DMEM
supplemented with 20% FBS, penicillin and streptomycin was
slowly added. Cells were allowed to autogrow for 2 weeks and then
passaged until enough cells were obtained. Cells were then
maintained in DMEM supplemented with 10% FBS, penicillin
and streptomycin at 37uC in a humidified atmosphere of 5% CO2.
Reverse-transcriptase polymerase chain reaction (RT-PCR)
RNA was isolated from cultured SMCs using Nucleospin RNA
II 50 Preps (Fisher Scientific) according to the manufacturer’s
instruction. Single-stranded cDNA was synthesized from 1 mgo f
total RNA using 0.5 mg random primers and 200 units of M-MLV
reverse transcriptase (Promega). PCR of the AT1 receptor and the
MAS receptor were carried out. The sequences of PCR primers
for AT1-R were 59-GCATCATCTTTGTGGTGGG-39 (sense)
and 59-ATCAGCACATCCAGGAATG-39 (anti-sense) as de-
scribed elsewhere[50], which generated a 690 bp PCR product.
The PCR primer sequences for the MAS receptor were, 59-
GGAACAGGACGGAGGTTACA-39 (sense) and 59-AGTCAG-
GAGGTGGAGAGCAA-39 (anti-sense), which produced a
395 bp amplicon. The PCR products were analyzed by agarose
gel electrophoresis to verify that they had the expected sizes and
were subsequently further verified by sequencing.
Measurement of cell proliferation
Some numbers of SMCs were seeded in different wells on 6-well
tissue culture plates, cultured in the presence of 1% FBS and
stimulated with Ang-(1-7) (10
27 M) or Ang II (10
27 M) or both
(Ang-(1-7) was added 10 minutes before the addition of Ang II). In
some conditions, cells were preincubated with losartan (10
26 M)
or A-799 (10
26 M) for 5 minutes followed by treatment with Ang
II or Ang-(1-7). The medium was changed and the cells were
restimulted every 24 hours. After four days, cells were removed
from each well using trypsin/EDTA and cell numbers were
counted by a Vi-CELL cell viability analyzer (Beckham Counter).
Migration assay
SMC migration was measured using a previously described
method [51,52]. Briefly, cells were grown to confluence on 6-well
plates. Parallel lines were drawn with a maker pen on the back of
each well. Liner wounds were made vertical to these parallel lines
by scraping each well with a sterile 200-uL pipette tip. Cells were
then rinsed twice with serum-free medium to remove cellular
debris. Images besides each crossing of parallel lines and wounds
were obtained using an Olympus inverted microscope equipped
with a camera. Cells were incubated with or without losartan
(10
26 M) or A-779 (10
26 M) for 5 minutes, then with or without
the addition of Ang II (10
27 M) or Ang-(1-7) (10
27 M), or with the
addition of Ang-(1-7) 10 minutes before addition of Ang II
(10
27 M). After 24 hours, images were taken again besides each
crossing. ImageJ software was used to measure the distance
between two edges of each wound. Data are presented as moving
distance, which is the difference in the distances between two
edges at the same crossing at 0 h and 24 h.
Western blotting
SMCs in serum-free media were incubated with or without
Ang-(1-7) (10
27 M)for 5 minutes. Ang II (10
27 M) was then added
and incubation was continued for an additional 30 minutes. Cell
lysates were prepared in lysis buffer (1% SDS, 62.5 mM Tris-HCl,
pH 7.8) containing protease inhibitor cocktail and phosphatase
inhibitor cocktail (Sigma Aldrich) and protein concentrations were
measured by a Bradford assay. Solubilized proteins (20 ug/well)
were separated in 10% SDS-polyacrylamide gel by electrophoresis
and transferred to nitrocellulose membranes. In the presence of
5% nonfat milk in Tris-buffered saline Tween 20 to block
nonspecific binding, the membranes were hybridized overnight
with an antibody for phosphorylated ERK1/2 (anti-phospho-
ERK1/2, 1:2000) or an antibody for total ERK1/2 (anti-total
ERK1/2, 1:1000), followed by incubation with a second antibody
coupled to horseradish peroxidase. Immunoreactive bands were
detected using a chemiluminescence (ECL) system and X-ray
films. Densitometric analysis of bands was performed using Adobe
Photoshop software.
Statistical analyses
All results are expressed as mean 6 SEM. The data were
evaluated by paired t-test and confirmed by Wilcoxon test. A value
of P,0.05 was considered significant.
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